SEC Filing Summary: Matinas Biopharma Holdings, Inc. (MTNB)
Business Context and Reporting Period
This Form 8-K was filed by Matinas Biopharma Holdings, Inc. on November 20, 2023. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company is incorporated in Delaware and its principal executive offices are located in Bedminster, New Jersey.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation update rather than a financial results report.
Material Changes
There are no material changes to financial performance or operational status reported in this document. The sole material event is the update of the company's Corporate Presentation intended for use at conferences and investor meetings.
Guidance, Outlook, and Risks
- Management Commentary: The company updated its Corporate Presentation (Exhibit 99.1) to reflect current information for investor communications.
- Legal Status of Information: The information contained in Item 7.01 and the attached Corporate Presentation is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section. It is not incorporated by reference into other filings unless expressly stated.
- Risks and Contingencies: No specific risks or contingencies are detailed in the body of this 8-K filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Presentation dated November 20, 2023) for the actual content of the updated outlook and operational details.
- Verify that the updated presentation has not been incorporated by reference into other regulatory filings.
- Consult the most recent 10-Q or 10-K for actual financial metrics, as this 8-K contains no financial data.